Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Organon and Co
Age
0–1
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to \<24 months of age at the Screening visit.
Clinical diagnosis of atopic dermatitis (AD), AD covering \>5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
You may not be if
Significant neurological disorder or history of seizure
Know clinically significant cardiac rhythm or cardiac disorder
History of sudden infant death in a sibling
Clinically significant chromosome abnormality
History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
Diseases that could cause pruritic and/or sleep disruption
Immunocompromised
Current chronic or acute infection requiring treatment
Use of prohibited medication(s) or procedure(s)
Use of prohibited medications by breastfeeding mother if breastfeeding participant
Clareo Health | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
